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Background: Surgery plus adjuvant radiotherapy is standard care for locally advanced
prostate cancer (stage pT3R1). Intraoperative low-energy photon radiotherapy offers
several advantages over external beam radiotherapy, and several systems are now
available for its delivery, using spherical applicators, which require only limited shielding.
The aim of this study was to evaluate the feasibility of this technique for the prostate bed.
Materials and methods: Applicators were assessed using MRI image data and
cadaveric dissection. In cadavers, targeted tissues, defined as a urethral section, both
neurovascular bundle sections, the bladder neck and the beds of the seminal vesicles,
were marked with metallic surgical clips. Distances between clips and applicator were
measured using CT. A dosimetric study of the application of 12Gy at 5mm depth was
performed using CT images of prostatectomized cadavers.
Results: Using MRI images from 34 prostate cancer patients, we showed that the ideal
applicator diameter ranges from 45 to 70mm. Using applicators of different sizes to
encompass the prostate bed in nine cadavers, we showed that the distance between
target tissues and applicator was <2mm for all target tissues except the upper extremity
of the seminal vesicles (19mm). Dosimetric study showed a good dose distribution in all
target tissues in contact with the applicator, with a low probability of rectum and bladder
complication.
Conclusion: Intraoperative radiotherapy of the prostate bed is feasible, with good
coverage of targeted tissues. Clinical study of safety and efficacy is now required.
Keywords: prostate cancer, prostatectomy, radiotherapy, intraoperative radiotherapy, combined modality therapy
Abbreviations:CT, computed tomography; EBRT, external beam radiotherapy; IORT, intraoperative radiation therapy; NTCP,
normal tissue complication probabilities.
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Introduction
Increasing numbers of patients are undergoing surgery for high-
risk prostate cancer (1). Despite adequate surgery, half of all
patients with locally advanced prostate adenocarcinoma (stage
pT3) will present in biochemical relapse in the fifth year after
operation, suggesting that many patients may not be curable by
surgery alone. Three studies have been evaluated the role of a
multi-modal approach that combines surgery with adjuvant irra-
diation in the prevention of relapse after prostatectomy (2–4).
All three studies showed reduction in the rate of biochemical
relapse, and one showed bettermetastasis-free survival and overall
survival among patients who had received adjuvant irradiation
(2). These studies emphasized that the main mode of relapse
in prostate cancer is local and that intensifying local treatment
reduces the risk of tumor recurrence (5). The relapse site is pri-
marily anastomotic in more than two-thirds of cases, but may
also occur at the level of the bladder neck, and occasionally
retrovesically (6). This means that the prostate bed boundaries
should be defined anteriorly by the posterior wall of the pubic
bone, posteriorly by the anterior wall of the rectum, laterally by
the levator ani muscles, caudally by the pelvic floor, and cranially
by the level of section of the vas deferens (7).
Post-operative irradiation is usually carried out between 3
and 6months after surgery in order to allow a better sphincter
recovery. However, this long-time period exposes the patients to
the risk of residual tumor growth and metastatic spread, espe-
cially for poorly differentiated tumors. To avoid delayed post-
operative radiotherapy, perioperative radiotherapy strategies have
been developed. Four studies have shown that it is possible to com-
bine prostatectomy with preoperative radiotherapy at the same
doses as those used for rectal cancers, without any increase in
perioperative toxicity (8). The complication rate appears compa-
rable to that observed among patients irradiated within 6months
of prostatectomy after long-term follow-up (9). Moreover, three
studies have demonstrated the feasibility of intraoperative radi-
ation therapy (IORT) using 7–12MeV electrons during radical
prostatectomy (10–12). Single fraction doses ranging from 10 to
22Gy were administered immediately before or after prostatec-
tomy. pT3 patients also received an additional dose of 45Gy to
the pelvis after surgery. No increase in long-term complications
was observed. The rectum was assessed intraoperatively to have
received a dose of 3.9Gy, well below its maximum tolerated dose,
which permitted additional external beam radiotherapy (EBRT)
if needed (10). However, the use of electrons implies that surgery
must be performed in a dedicated shielded operating room or that
the patient be moved to a bunker for the treatment delivery.
More recently, the use of low-energy photon IORT has
been developed for other cancer types, notably breast cancer
(Intrabeam™, Carl Zeiss Meditec, Iena, Germany and Axxent
eBx™ System, Xoft, San Jose, CA, USA) (13, 14). Isotropic x-
ray irradiation is delivered rapidly to the tissues surrounding the
tumor area during surgery. Compared with high-energy photon
EBRT, the rapid absorption of low-energy photons limits the dose
spread to surrounding tissues, with <35% of the dose delivered to
the surface of the applicator at a distance of 10mm. In contrast to
the extensive shielding required for electron therapy, IORT using
low-energy photons requires only limited shielding similar to that
required for diagnostic x-rays. Moreover, low-energy photons are
biologically more destructive than either high-energy photons
or electrons, since the relative biological efficacy (RBE) of low-
energy photons is estimated between 1.2 and 1.5, whereas the RBE
is 1 for high-energy photons or electrons (15). Treatment lasts
about 30–50min, depending on the size of the applicator and the
prescribed dose. Intraoperative irradiation is now routinely used
in breast cancer patients, with very good clinical short- and long-
term efficacy and tolerance (16). This irradiation reduces the delay
between surgery and radiotherapy and reduces the travel burden
induced by the repeated visits necessary for EBRT.
We performed a preclinical study using both the Intrabeam™
and theAxxent™ systems in prostate cancer patients and in prosta-
tectomized corpses to evaluate the feasibility of intraoperative
radiotherapy in prostate cancer.
Patients and Methods
This study was carried out in accordance with the recommen-
dations of local ethics committee with written informed consent
from all subjects.
Low-Energy Photon IORT Systems
Two systems are commercially available for low-energy photon
IORT. Both systems deliver a 50-kV beam.
Intrabeam™(Zeiss, Germany) uses a miniaturized accelera-
tor introduced in rigid or inflatable spherical applicators, which
range from 10 to 50mm in diameter. The prescribed dose is
delivered around the applicator with an isotropic distribution.
Axxent™(Xoft, CA, USA) uses a 2.25-mm diameter X-ray source
placed in an inflatable spherical or ovoid applicator whose diam-
eter varies from 30 to 70mm. The source can be moved into the
applicator tomodulate the dose distribution. This new technology
is called “electronic brachytherapy” (eBx). Table 1 and Figure 1
summarize these characteristics.
Evaluation of the Sphericity and Dimensions of
the Prostate Bed in Prostatectomized Cadavers
Radical prostatectomy without conservation of the neurovascular
bundles was performed in nine cadavers in the anatomy labora-
tory of the University of Nantes. Radio-opaque clips were placed
at potential recurrence sites, which were defined as the urethral
section, bladder neck, neurovascular bundles, anterior wall of the
TABLE 1 | Characteristics of Zeiss Intrabeam™ or Xoft Axxent eBx™
low-energy photon intraoperative radiotherapy (IORT).
Intrabeam™ Axxent eBx™
Photon max energy 50 keV 50 keV
Applicators Rigid or inflatable:
10–50mm
Inflatable:
30–70mm
Stalk length Rigid: 135mm 250mm
Inflatable: 65mm
Dose rate (Gy/min) 0.15 0.6
Delivery time (12Gy, 5mm depth,
50mm applicator) (min)
52.8 21
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FIGURE 1 | (A) Intrabeam: 50mm rigid (left) and balloon (right) applicators, stalk length= 135 and 65mm, respectively; (B) Xoft: 50–60mm applicator, stalk
length= 250mm.
rectum, and the beds of the seminal vesicles. After prostatec-
tomy and identification of target tissues, applicators (Intrabeam™
or Axxent™ applicators) were inserted in the prostate bed until
they were in contact with the urethral section of the pelvic
floor. The applicator was then applied to the anterior rectal wall,
as closely as possible to the clips marking the neurovascular
bundles. The most suitable size was selected visually. Finally,
the bladder was lowered to apply the bladder neck against the
applicator, and sutured to the pubic symphysis on both sides
of the applicator. A CT scan was later performed to mea-
sure the distance between the clips and the spherical applicator
(Figure 2).
MRI Evaluation of the Dimensions of the Prostate
Bed Prior to Surgery
To determine the size of the prostate bed prior to surgery
in prostate cancer patients, spheres of increasing diameter
(45–70mm) were generated on 3D-reconstructed T2-weighted
sequences (4mm thick) prostateMRI images using Iplan® (Brain-
Lab, Germany). The pelvic organs – prostate, rectum, seminal
vesicles, and the pubic symphysis – were contoured. The small-
est sphere to completely encompass the prostate volume was
considered the most suitable (Figure 3).
Dose Distribution and Estimation of the
Probability of Normal Tissue Complications
A 50-mm applicator (Intrabeam™ system) and a 50-to 60-mm
applicator (Axxent™ system) were inserted in the prostate bed
of two cadavers. CT images were then acquired. Pelvic organs
at risk (bladder and rectum) were delineated on the images.
Dose distribution was calculated using a Monte Carlo simulation
for the Intrabeam™ system (17) or using Brachyvision software
(Varian medical systems, San Jose, CA, USA) for the Axxent™
system.Dose–volume histogramswere computed. A dose of 12Gy
at 5mm depth, corresponding to 20Gy at the surface of the
applicator, was prescribed, similar to that used for breast cancer
IORT (16) and prostate bed IORT using electrons (10, 11). The
dose distributionwas computed to calculate normal tissue compli-
cation probabilities (NTCP) for rectum and bladder using relevant
radiobiological parameters (alpha/beta for rectum and bladder 5.4
and 7.5Gy, respectively) using EBRT and HDR models similar to
those outlined by Takam et al. (18).
Results
Evaluation of the Shape and Dimensions of the
Prostate Bed in Cadavers
Nine cadavers without prostate cancer (mean age 83, range
78–92) were dissected and prostatectomy without neurovascular
preservation performed. Applicators or plastic spheres were then
inserted in the prostate bed. Congruence with the anatomical
boundaries was evaluated visually when the sphere came into
contact with all target tissues. The best-adapted sphere measured
50mm in four cases, 60mm in four cases, and 50–60mm (ovoid
applicator) in one case.
Once the positioning had been optimized visually, CT scans
were performed to evaluate the congruence of the applicator to
the prostate bed and distances between the applicator and radio-
opaque clips were measured. In all cases, the congruence of the
applicator to the prostate bed was not affected by the shape of
the applicator, whether spherical (Intrabeam™) or slightly ovoid
(Axxent™) (Table 2).
The Axxent™ applicator can easily be inserted in a laparoscopic
trocar before placement, allowing it to be used whatever the
surgical approach chosen (open or laparoscopic, with or without
robotic assistance).
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FIGURE 2 | Positioning of Zeiss Intrabeam™(A) or Xoft Axxent eBx™[(B) through laparoscopic trocar] applicators and CT scans of prostatectomized
corpses with radiopaque clips located at different target tissues. U, urethra; ABN, anterior bladder neck; PBN, posterior bladder neck; LA, left apex; RA, right
apex.
FIGURE 3 | Graphical representation of the determination of applicator size on MRI images.
Rectal filling increased the distance between the applicator’s
surface and the urethral or neurovascular bundle clips by up
to 15mm (cadavers 2 and 6). After removing rectal stool, this
distance reduced to <2mm (cadaver 6). Clips at the distal extrem-
ity of the seminal vesicles were always located more than 2mm
from the applicator’s surface in the first two cadavers, so the
marking of this target site was abandoned in the next six cadav-
ers studied. In the other cases, the CT scan measured distance
between the applicator’s surface and clips ranged between 0 and
6mm. The size of the applicator did not influence the distance
between the clips and applicator’s surface.
MRI Evaluation of the Dimensions of the Prostate
Bed Prior to Surgery
To determine the dimensions of the prostate bed in a larger
cohort of patients, we simulated the positioning of applicators of
different sizes in 34 prostate cancer patients usingMRI (Figure 3).
Prostate volume ranged from 25 to 106ml (median= 39.7ml).
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TABLE 2 | Distance (millimeter) between radio-opaque clips and applicator surface on CT scan in nine prostatectomized cadavers.
#1 #2 #3 #4 #5 #6 #6a #7 #8 #9
Age 82 79 92 90 84 80 80 80 78 83
Applicator size (mm) 60 60 60 60 50 50 50 50 50 50–60
Applicator type rig. S rig. S rig. S rig. S rig. IB rig. IB rig.IB rig. IB inf. IB inf. Ax
Urethra – 14 – – – 6 – – – –
Ant BN – – – – – – – – – –
Post BN – – – – – – – – – –
Retrovesical – – – – 1.3 – – – nd 1.1
Left apex 1.5 15 – – – 3 – – – –
Right apex – 9 – – – 1.5 – – 4 –
Left NVB – 10 – – nd – – – nd –
Right NVB – – – – – – – – nd –
Left base – – – – – – – – – –
Right base – – – – – – – – – –
Left distal SV 19 10 nd nd nd nd nd nd nd nd
Right distal SV 5 2.5 nd nd nd nd nd nd nd nd
Rectum Empty Full Empty Empty Empty Full Empty Empty Empty Empty
aSame cadaver after rectal emptying.
rig. S, rigid plastic sphere; rig. IB, rigid intrabeam applicator; inf. IB, inflatable intrabeam applicator; inf. Ax, inflatable Axxent applicator; –, 0mm; BN, bladder neck; NVB, neurovascular
bundles; SV, seminal vesicles; nd, not determined.
FIGURE 4 | Distribution of the diameter of the applicator among 9
prostatectomized cadavers (plain bars), and in MRI images from 34
prostate cancer patients (empty bars).
After 3D reconstruction and virtual applicator testing, the size
ranged between 50 and 70mm. In 78% of patients, the applicator’s
diameter ranged between 50 and 60mm, confirming the cadaveric
measurements (Figure 4). Neither prostatic volumes nor prostate
dimensions were predictive of the ideal applicator diameter (data
not shown).
Dose Distribution and Estimation of the
Probability of Normal Tissue Complications
Dose distribution was calculated in two cadavers in which a 50-
mm applicator (Intrabeam™ or Axxent™) had been inserted. A
similar dose distribution to target tissues in contact or in the
close vicinity of the applicator was obtained (Figure 5). In the
cadaver with rectal distension (cadaver 6), the dose to the urethra
was decreased by 28% (full rectum: 8.6Gy; empty rectum: 12Gy).
Using either the EBRT (e) or HDR (h) model, the NTCP for the
rectum was 2.3% (e) and 1.0% (h) for the Intrabeam™ irradiation
and <1% (e) and (h) for the Axxent™ irradiation. The NTCP for
the bladder was 2.8% (e) and 2.0% (h) for the Intrabeam™ irra-
diation and <1% (e) and (h) for the Axxent™ irradiation. NCTP
were lower with (h) because the distances from the applicator to
the bladder and the rectum were larger for those cases.
Discussion
We have shown that low-energy photon IORT using spherical
applicators can be adapted for treatment of the prostate bed with
the exception of the upper extremity of the seminal vesicles, and
that the radiation dose received by the pelvic organs at risk is
consistent with a low probability of acute and late toxicity.
The spherical shape of the applicators was suitable for the
anatomical configuration of the prostate bed. The applicator shape
could be fully spherical (Intrabeam™) or ovoid (Axxent™) without
incongruence of the applicator to the prostate bed. However, it
is important to empty the rectum since the distance between the
applicator’s surface and the urethral section was increased in the
cadaver with a full rectum, which significantly reduced the dose
to this target tissue.
The applicator positioning was standardized. It was impacted
in the rectum in order to be in contact with the neurovascular
bundle section. Then, it was applied close to the urethral section.
Finally, bladder neck was lowered into contact with the applicator.
The choice of the size was visual, testing different applicators.
Using this approach (standardized positioning verified visually),
CT scan confirmed adequate positioning of the applicator and
good dosimetric coverage in all cadavers, with the exception of
the one whose rectum was initially full.
Applicators could be rigid (Intrabeam only) or inflatable (Intra-
beam and Axxent). This property had no effect neither on posi-
tioning in cadaver nor on CT scan image quality. However,
inflatable applicators could easily be inserted in a laparoscopic
trocar before placement, allowing them to be used whatever the
surgical approach chosen (open or laparoscopic, with or without
robotic assistance). Among inflatable applicators, we found that
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FIGURE 5 | Dose distribution in targeted tissues using Zeiss Intrabeam™(A) or Xoft Axxent™(B).
the Axxent one seemed more convenient because (1) the longer
stalk allows a better adaptation to the anatomy of patients and (2)
the four times higher dose rate should reduce operating time.
We selected areas at risk – positive margins and/or areas fre-
quently involved in local recurrences (19) – as target tissues, and
determined whether all target tissues would receive the prescribed
dose. Our results showed that all target tissues would be irradiated
at the same dose, including the proximal, but not the distal, part of
the seminal vesicles. Invasion into the seminal vesicles is usually
limited to the proximal part; the distal part is invaded only in
20% of pT3b cases (20), so IORT would only miss a very limited
number of remaining tumor cells. Moreover, pT3b patients are at
high risk of metastatic disease (21), which implies that systemic
therapies would be probably more important than increased local
treatment in this clinical situation.
We simulated a dose of 12Gy at a 5-mm depth, 20Gy at the
surface of the applicator. The 5-mm depth encompassed all radio-
opaque clips, which suggests that all target tissues would receive a
dose ranging between 12 and 20Gy, which is equivalent to 36–92
and 46–123Gy in 2Gy fractions for alpha/beta equal, respectively,
to 3 and 1.5Gy (22). We selected a dose of 12Gy at a 5-mm
depth since (1) this dose is routinely used for breast IORT (16),
(2) no increased acute and late toxicity was seen in clinical series
following a 12Gy irradiation using IORT with electrons, and
(3) it may be combined with post-operative irradiation without
increasing acute and late toxicity (10–12). Higher single-dose
treatment seems to be well tolerated, since 22Gy in one single
fraction of IORT using electrons did not increase perioperative or
late toxicity (12).
Both Intrabeam and Axxent systems deliver low-energy pho-
tons (50 keV) limiting shielding measures necessary to avoid
medical staff exposure. In our institution, we performed mea-
sures with Intrabeam system (40mm applicator, 50 kV, 40μA)
before beginning IORT for breast cancer. We found a dose rate of
1700μSv/h at 1m from the source and 1.6μSv/h behind amovable
lead shield at 3m from the source. As dose rate decreases when
applicator diameter increases, the exposure should be lower with
a 50-mm applicator. Slightly similar dose rates are observed with
Axxent system with a dose rate of 2000μSv/h at 30 cm from the
treated area that decreases more than 95% behind a movable lead
shield (23).
The main limitation of our study is the determination of the
NTCP. NTCP models are based on fractionated irradiation. To
determine the complication probabilities of low-energy photon
IORT, we assumed that this model could be applied to high single-
dose irradiation, which is not definitively proven (24). This model
has been developed for high-energy photons; models for low-
energy photons are lacking. We could not specifically determine
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the probability of urethral stenosis using this NTCP model. One
adjuvant radiotherapy study showed an increased frequency of
urethral stenosis (2), whereas two other studies did not show any
differences between adjuvant irradiation and observation (3, 4).
A clinical phase I study will be required to carefully evaluate the
perioperative toxicity of low-energy photon IORT.
Conclusion
Our study suggests that low-energy photon IORT, using spherical
applicators, is feasible during radical surgery for localized prostate
cancer. Selection of the precise applicator and low-energy photon
IORT machine will depend on patient characteristics (prostate
volume, prostate depth). The current indication for adjuvant
radiotherapy is pT3 disease based on the post-operative patho-
logical examination (25). It would be reasonable to select patients
whomight benefit from low-energy photon IORT prior to surgery
based on the probability of pT3 stage disease: according to PSA
level, Gleason score >7, or cT3a disease with resectable disease
or extra-capsular extension on MRI, though patients with T3b
disease should be excluded (26).
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